GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma

GlaxoSmithKline announced on Wednesday that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of the chronic lung disease asthma as prophylactic therapy in patients aged 12 years and older. 


Read the source article at GlaxoSmithKline (GSK)

About the Author

Leave a Reply